[Original Text in Spanish}
He also presented the National Strategy of Action on Resistance to Antimicrobials
The Federal Commissioner for Protection against Health Risks, Julio Sanchez and Tépoz, warned that the challenge of the health authorities in the world is to prevent and prevent in their countries are marketed low quality or counterfeit medical products, as they do not guarantee quality , safety and efficacy.
By participating in the panel “The critical role of regulation in combating low-quality and counterfeit medical products”, in the framework of the 71st World Health Assembly, in Geneva, Switzerland, held that “quality medical products Substandard and counterfeit are a risk to the health of the population and it is up to us, as regulatory authorities, to avoid commercialization in our countries at all costs. ”
“The National Drug Regulatory Authorities require increasingly diverse and complex regulatory competencies to comply with the safety and quality of regulated medical products and thereby prevent the entry into the market of counterfeit medical products of low quality in the market. The challenges are significant and could lead to various economic and public health risks that would negatively impact on mortality, morbidity, quality of life, patient and consumer productivity, as well as on the general economic well-being of the countries, “said the owner. the COFEPRIS.
Before representatives of the World Health Organization (WHO) and health authorities of various countries, stressed that the safety and quality of medical products and greater access to them, the transparency and accuracy of information in regulatory acts, as well as the adoption of timely methodologies based on evidence to remove suspicious products from the market and thus prevent damage and mitigate risks to public health, are essential to efficiently regulate potential health risks.
In another meeting, Julio Sánchez and Tépoz, with the representation of the Government of Mexico, presented the National Strategy of Action on Resistance to Antimicrobials.
The Federal Commissioner explained that the 71st World Health Assembly addressed issues of public health, environment and climate change; global shortage of medicines and vaccines and their access; global strategy and public health action plan; innovation and intellectual property; global governance to guarantee sustainable global actions; nutrition of the mother, the infant and the young child; as well as the dimension of public health in the world drug problem.
Source: https://www.gob.mx/cofepris/articulos/reto-de-las-autoridades-sanitarias-evitar-que-se-comercialicen-productos-medicos-falsos-y-de-baja-calidad-jsyt-158040?idiom=es
